Evidence map›Paper›PMID 9417473›Full record

ReviewThe Journal of experimental medicine1997

What goes up must come down: the emerging spectrum of inhibitory receptors.

W M Yokoyama

Abstract readReviewComment
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.Proceedings of the National Academy of Sciences of the United States of America · 1998
    Article
  8. The paired Ig-like receptor PIR-B is an inhibitory receptor that recruits the protein-tyrosine phosphatase SHP-1.Proceedings of the National Academy of Sciences of the United States of America · 1998
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

W M YokoyamaHoward Hughes Medical Institute, Rheumatology Division, Washington University School of Medicine, St. Louis, Missouri 63110, USA. yokoyama@imgate.wustl.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigens, CDAnimalsHistocompatibility Antigens Class IHumansImmune ToleranceIntracellular Signaling Peptides and ProteinsKiller Cells, NaturalLeukocyte Immunoglobulin-like Receptor B1LigandsMicePhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphoric Monoester HydrolasesProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine PhosphatasesReceptors, FcAntigens, CDHistocompatibility Antigens Class IINPPL1 protein, humanIntracellular Signaling Peptides and ProteinsLeukocyte Immunoglobulin-like Receptor B1LigandsLILRB1 protein, humanPhosphatidylinositol-3,4,5-Trisphosphate 5-PhosphatasesPhosphoric Monoester HydrolasesProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine PhosphatasesPTPN11 protein, humanPtpn11 protein, mousePTPN6 protein, humanPtpn6 protein, mouseReceptors, FcReceptors, Immunologic

Identifiers

PMID9417473
PMCPMC2199159

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.